Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper gastrointestinal involvement (CROHNEX study),Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper gastrointestinal involvement (CROHNEX study)
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-08-18 , DOI: 10.1111/apt.16547
Empar Sainz ₁ , Yamile Zabana ₁ , Isabel Miguel ₂ , Agnès Fernández-Clotet ₁ , Belén Beltrán ₃ , Laura Núñez ₄ , María José García ₅ , María Dolores Martín-Arranz ₄ , Eva Iglesias ₆ , Fiorella Cañete ₁ , Ana Gutiérrez ₇ , Marta Piqueras ₁ , Isabel Pérez-Martínez ₈ , Luis Bujanda ₉ , Iago Rodríguez-Lago ₁₀ , María José Casanova ₄ , Pablo Navarro ₃ , Raquel Vicente ₁₁ , Olga Merino ₁₂ , Alicia Algaba ₄ , Cristina Rodríguez ₁₃ , José M Huguet ₃ , Fernando Fernández-Bañares ₁ , Eugeni Domènech ₁ , Maria Esteve ₁ ,

Affiliation

Crohn's disease (CD) with upper gastrointestinal involvement (UGI) may have a more aggressive and refractory course. However, evidence on this phenotype of patients is scarce.

中文翻译：